By Fineline Cube 
Optoseeker Biotech, a leader in advanced life science instrumentation, and BioMap, a pioneer in life science AI, announced a strategic collaboration today aimed at significantly accelerating the development of novel antibody therapeutics. This partnership combines Optoseeker’s proprietary high-throughput cell screening technology, the OptoBot platform, with BioMap’s expertise in domain-specific life science AI.
Innovative Partnership
The collaboration is designed to address critical bottlenecks in the drug discovery process. By integrating Optoseeker’s OptoBot platform with BioMap’s AI capabilities, the partnership creates a streamlined workflow that can identify promising antibody candidates with unprecedented speed and precision. This innovative approach has the potential to transform the development of new treatments.-Fineline Info & Tech